Core Viewpoint - The company, Kaineng Health, is expanding its investment in the cell industry by acquiring 100% equity stakes in several subsidiaries of Yuanneng Group for a total transaction price of 204 million yuan, aiming to enhance its growth trajectory in the health sector [1][4]. Group 1: Transaction Details - Kaineng Health's wholly-owned subsidiary, Hainan Kaineng Cell Industry, signed an equity acquisition agreement with Yuanneng Group and its subsidiary Yuanneng Lishui, purchasing stakes in Shanghai Yuantian Biotechnology, Lishui Dongxin Pharmaceutical, Shanghai Kelemao Biotechnology, and Jiyuan Meiyu Biotechnology for 204 million yuan [1][4]. - The transaction involves related parties, as Kaineng Health holds a 43.7% stake in Yuanneng Group, with its chairman and actual controller being the same individual as Yuanneng Group's actual controller [3]. Group 2: Background of Yuanneng Group - Yuanneng Group was established in July 2014 with an initial investment of 100 million yuan, which has increased to a registered capital of 546 million yuan as of now [2][3]. - The group operates in the Zhangjiang Biomedical Industry Base, covering 80 acres with a total construction area of approximately 80,000 square meters, focusing on third-party cell storage and downstream applications such as stem cell drug development and immune cell drug research [2][3]. Group 3: Strategic Intent - Kaineng Health aims to strengthen its investment layout in the cell industry, leveraging its existing business in health and environmental purification to create a second growth curve [4]. - The company plans to provide resource support to the acquired entities, enhancing their development and increasing investment in the health sector to diversify its product offerings and improve competitive strength [4].